Format

Send to

Choose Destination
Ann Intern Med. 2019 Jul 2;171(1):51-57. doi: 10.7326/M19-0961. Epub 2019 Apr 23.

National Institutes of Health Pathways to Prevention Workshop: Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention.

Author information

1
Icahn School of Medicine at Mount Sinai, New York, New York (A.S.).
2
Yale School of Medicine, Yale School of Public Health, New Haven, Connecticut (H.A.).
3
Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (D.B.).
4
University of California, Irvine, California (S.T.C.).
5
University of South Carolina, Arnold School of Public Health, Columbia, South Carolina (M.L.).

Abstract

On 30 and 31 October 2018, the National Institutes of Health convened the Pathways to Prevention (P2P) Workshop: Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention to assess the available evidence on long-term (>3 years) use of drug therapies to prevent osteoporotic fractures and identify research gaps and needs for advancing the field. The workshop was cosponsored by the NIH Office of Disease Prevention (ODP), National Institute of Arthritis and Musculoskeletal and Skin Diseases, and National Institute on Aging. A multidisciplinary working group developed the agenda, and an Evidence-based Practice Center prepared an evidence report through a contract with the Agency for Healthcare Research and Quality to facilitate the discussion. During the 1.5-day workshop, invited experts discussed the body of evidence and attendees had the opportunity to comment during open discussions. After data from the evidence report, expert presentations, and public comments were weighed, an unbiased independent panel prepared a draft report that was posted on the ODP Web site for 5 weeks for public comment. This final report summarizes the panel's findings and recommendations. Current gaps in knowledge are highlighted, and a set of recommendations for new, strengthened research to better inform the long-term use of osteoporotic drug therapies is delineated.

PMID:
31009943
DOI:
10.7326/M19-0961

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center